A 14-year-old boy with Duchenne muscular dystrophy has regained some strength and function in his muscles following treatment with an experimental gene therapy from Solid Biosciences, the boy’s father tells STAT.

And although it’s just a single case report — with additional details being gleaned from the father’s posts in a closed Facebook group — it’s playing a part in easing investor concerns about the safety of the Solid treatment.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy